Hamilton acquires the microdosing company BioFluidiX

BioFluidix is now part of the Hamilton Bonaduz AG

07-Dec-2022 - Hamilton announced that it is expanding its microfluidics product range with the acquisition of the microdosing company, BioFluidiX. BioFluidiX’s patented microdosing processes enable precise dosing in the nano and picoliter range and is an exciting addition to Hamilton’s liquid automation ...

Safe from over- or underdosing

Long-lasting and precise dosing of medication thanks to an oil-hydrogel mixture

24-Feb-2020 - Using a mixture of oil droplets and hydrogel, medical active agents can be not only precisely dosed, but also continuously administered over periods of up to several days. The active agents inside the active droplets are released at a constant rate, decreasing the risk of over- or ...

ViscoTec Asia Grows and Expands its Facility

More office space, larger labs and meeting rooms in Singapore

14-Feb-2020 - Great joy and expectations at the same time characterize the mood of the ViscoTec Asia team these days. The move to the new office is done. In the new office there is an increased office space with 1700 sqft. An about 50% larger lab for testing and training and a much larger meeting room gives ...

Do some prescriptive sleeping pills posses a danger?

Novel class of sleeping pills might prevent ability to wake in response to threat

15-Jan-2019 - In a trial of one of the main class of prescription sleeping pills, half the participants slept through a fire alarm as loud as someone vacuuming next to their bed. But a newer alternative preserves the ability to wake in response to danger signals, according to a new research. The study showed ...

One dose of aspirin doesn’t fit all

17-Jul-2018 - About one billion people worldwide take regular aspirin, usually to prevent heart attacks or strokes. Researchers have shown that ‘one-dose-fits-all’ use of aspirin to prevent heart attacks, stroke or cancer, is ineffective or harmful in the majority of people, and that a more tailored strategy ...

Personalize your medication dosages

Initial clinical tests show that biosensors could pave the way for a personalized antibiotherapy in the future

18-Jul-2017 - Personalized drug therapy, adjusting the dose, dosage intervals, and the duration of treatment to fit individual patients' needs, are getting more and more important. Frequently, medications are dosed in such a way that each patient receives the same standardized amount of a certain drug. ...

BioInvent reports clinical hold on BI-505 phase II study

09-Nov-2016 - BioInvent International has received verbal notice from the U.S. Food and Drug Administration that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInvent has not ...

Freie Universität first institution in Germany to integrate medication management into the pharmacy study program

01-Nov-2016 - The Institute of Pharmacy at Freie Universität Berlin is the first of its kind in Germany to integrate the field of medication management into the education of its pharmacy students. The goal is to put theoretical knowledge into practice even before the students have completed their study ...

Positive result for POWTECH and TechnoPharm 2014

More international: over one-third of the exhibitors and visitors come from abroad

07-Oct-2014 - POWTECH and TechnoPharm 2014 can be summed up positively after three days of productive exhibition activity and knowledge transfer. With altogether 929 exhibitors from 30 countries and some 15,000 trade visitors, it is the world’s largest and most important event for new trends in processing and ...

Restoring 'exhausted' HIV-fighting immune cells

Protein could prove a promising new drug target

04-Dec-2013 - Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling ...